Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Nishio

Showing results (391-400 of 409) with videos related to

Pageof 41
Sort By:
Journal of Cardiology|August 11, 2001
[Relationship between endothelial dysfunction and nitric oxide production in young male smokers]T Hori, T Matsubara, T Ishibashi, et al.
ESMO Open|June 30, 2023
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing resultsE B Garon, M Reck, K Nishio, et al.
Japanese Journal of Clinical Oncology|May 26, 1999
National average for the process of radiation therapy in Japan by Patterns of Care StudyK Tanisada, T Teshima, T Inoue, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|November 22, 2014
Leptin improves fatty liver independently of insulin sensitization and appetite suppression in hepatocyte-specific Pten-deficient mice with insulin hypersensitivityS Yamamoto-Kataoka, K Ebihara, M Aizawa-Abe, et al.
Oncogene|March 28, 2017
MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formationK Otsubo, H Goto, M Nishio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)K Takeuchi, Y Togashi, Y Kamihara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)H Yoshioka, K Azuma, N Yamamoto, et al.
Bone Marrow Transplantation|March 23, 2011
Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHDJ Sugita, T Matsushita, H Kashiwazaki, et al.
ESMO Open|March 23, 2024
Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCMS Watanabe, H Yoshioka, H Sakai, et al.
ESMO Open|February 14, 2022
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patientsK J O'Byrne, K H Lee, S-W Kim, et al.
Pageof 41

Showing results (391-400 of 409) with videos related to

Sort By:
Pageof 41
Journal of Cardiology|August 11, 2001
[Relationship between endothelial dysfunction and nitric oxide production in young male smokers]T Hori, T Matsubara, T Ishibashi, et al.
ESMO Open|June 30, 2023
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing resultsE B Garon, M Reck, K Nishio, et al.
Japanese Journal of Clinical Oncology|May 26, 1999
National average for the process of radiation therapy in Japan by Patterns of Care StudyK Tanisada, T Teshima, T Inoue, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|November 22, 2014
Leptin improves fatty liver independently of insulin sensitization and appetite suppression in hepatocyte-specific Pten-deficient mice with insulin hypersensitivityS Yamamoto-Kataoka, K Ebihara, M Aizawa-Abe, et al.
Oncogene|March 28, 2017
MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formationK Otsubo, H Goto, M Nishio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)K Takeuchi, Y Togashi, Y Kamihara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)H Yoshioka, K Azuma, N Yamamoto, et al.
Bone Marrow Transplantation|March 23, 2011
Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHDJ Sugita, T Matsushita, H Kashiwazaki, et al.
ESMO Open|March 23, 2024
Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCMS Watanabe, H Yoshioka, H Sakai, et al.
ESMO Open|February 14, 2022
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patientsK J O'Byrne, K H Lee, S-W Kim, et al.
Pageof 41